Sacubitril / Valsartan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), NICE (England) and SMC (Scotland), among others, recommended or restricted sacubitril / valsartan, while AOTMIT (Poland) did not recommend it.
Assessment has run over 9.1 years, from 3 Nov 2015 at AWMSG (Wales) to 13 Dec 2024 at TLV (Sweden).
PBAC (Australia) changed its position: not recommended in 2016, recommended by 2024, after a resubmission.
No assessment is on file from HAS (France), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 5 of 12 records date from 2023 or later.
3 distinct indication wordings are recorded for sacubitril / valsartan by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 12 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess sacubitril / valsartan, on 3 Nov 2015; AOTMIT (Poland) did not open a file until 12 Sep 2023 — a wide spread of 7.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 12 dated records fall in 2016 alone.
Restriction is doing real work here: 3 of 9 decisive outcomes narrowed sacubitril / valsartan to a subgroup rather than accepting or refusing it outright, at TLV (Sweden) and ZIN (Netherlands).
3 of the 9 agencies here assessed sacubitril / valsartan more than once, TLV (Sweden) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for sacubitril / valsartan.
The full ledger for sacubitril / valsartan reads 4 recommended, 3 restricted, 2 not recommended and 1 no benefit, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 13 Dec 2024 | Entresto ingår i högkostnadsskyddet med utökad subvention och ny beredningsform för barn | restricted subsidy | source |
| PBAC (Australia) | 2024 | Chronic heart failure (CHF) | Recommended | source |
| G-BA (Germany) | 7 Dec 2023 | Entresto — benefit assessment §35a | added benefit: not proven | source |
| AOTMIT (Poland) | 12 Sep 2023 | Entresto reimbursement recommendation | not recommended | source |
| ZIN (Netherlands) | 28 Apr 2023 | GVS-advies sacubitril/valsartan (Entresto®) uitbreiding bijlage 2-voorwaarden | conditions amended (GVS) | source |
7 further decisions for sacubitril / valsartan, across 7 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- vericiguat — divergent outcome (recommended vs not recommended) on a shared indication
- ivabradine — divergent outcome (recommended vs not recommended) on a shared indication
- valsartan — same ATC class C09C — Renin-angiotensin system
- candesartan — same ATC class C09C — Renin-angiotensin system
- losartan — same ATC class C09C — Renin-angiotensin system
- olmesartan — same ATC class C09C — Renin-angiotensin system
Coverage: 12 decisions for sacubitril / valsartan from 9 agencies, 2015 to 2024. Data to 7 Sep 2026. ATC class C09C — Renin-angiotensin system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.